喹诺酮类化合物的合成、体外抗肿瘤活性与分子对接研究

李杰, 金懿, 吕延文, 许建帼

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (22) : 1913-1917.

PDF(1141 KB)
PDF(1141 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (22) : 1913-1917. DOI: 10.11669/cpj.2016.22.004
论著

喹诺酮类化合物的合成、体外抗肿瘤活性与分子对接研究

  • 李杰, 金懿, 吕延文, 许建帼*
作者信息 +

Synthesis, Antitumor Activity and Molecular Docking of Quinolone Derivatives

  • LI Jie, JIN Yi, LV Yan-wen, XU Jian-guo*
Author information +
文章历史 +

摘要

目的 研究新型喹诺酮类衍生物的合成方法及抗肿瘤活性。方法 以环丙沙星结构为基础,采用基于片段的药物设计方法合成目标化合物,以MTT法测试目标化合物对A549、HL-60、Hela等肿瘤细胞的抑制活性。并运用Discovery Studio软件的Libdock模块对目标化合物进行分子对接研究。结果 合成了8个新的目标化合物,体外均显示潜在的抗肿瘤活性。结论 该类喹诺酮类衍生物的抗肿瘤活性值得进一步研究。

Abstract

OBJECTIVE To study the synthesis and antitumor activity of novel quinolone derivatives. METHODS Based on the structure of ciprofloxacin, the objective substances were designed and synthesized according to the principle of fragment-based drug discovery. Their anti-tumor activities in vitro were evaluated against A549, HL-60, and Hela cells by MTT assay. Molecular docking studies were performed with the Libdock protocol of Discovery Studio to afford the ideal interaction mode of the compound with the binding site of the Topo Ⅰ. RESULTS Eight novel compounds were synthesized and showed potential antitumor activities. CONCLUSION The antitumor activities of the synthesized quinolone derivatives are worthy of further study.

关键词

喹诺酮类化合物 / 抗肿瘤活性 / 分子对接 / Topo I抑制剂

Key words

quinolone derivatives / antitumor activity / molecular docking / Topo Ⅰ inhibitor

引用本文

导出引用
李杰, 金懿, 吕延文, 许建帼. 喹诺酮类化合物的合成、体外抗肿瘤活性与分子对接研究[J]. 中国药学杂志, 2016, 51(22): 1913-1917 https://doi.org/10.11669/cpj.2016.22.004
LI Jie, JIN Yi, LV Yan-wen, XU Jian-guo. Synthesis, Antitumor Activity and Molecular Docking of Quinolone Derivatives[J]. Chinese Pharmaceutical Journal, 2016, 51(22): 1913-1917 https://doi.org/10.11669/cpj.2016.22.004
中图分类号: R97   

参考文献

[1] ERTL P, JELFS S, MHLBACHER J, et al. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds [J]. J Med Chem, 2006, 49(15):4568-4573.
[2] SISSI C,PALUMBO M. The quinolone family:from antibacterial to anticancer agents [J]. Curr Med Chem Anticancer Agents, 2003, 3(6):439-450.
[3] MUGNAINI C, PASQUINI S, CORELLI F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry [J]. Curr Med Chem, 2009, 16(14):1746-1767.
[4] XU Q J, HOU L L, WU Z F, et al. Synthesis and antitumor evaluation of fluoroquinolon C3 s-triazole oxadizaole methylsufide derivatives of ofloxacin [J]. Chin Pharm J(中国药学杂志), 2014, 49(7):609-612.
[5] LI T, GAO L Z, XIE Y S, et al. Synthesis and antitumor activity fluoroquinolon-3-yloxadiazole sulfanylacetylhydrazone derivatives [J]. Chin Pharm J(中国药学杂志), 2014, 49(24):2206-2209.
[6] GAO L Z, LI T, XIE Y S, et al. Synthesis and antitumor activity of fluoroquinolone-3-yl s-triazole sulfanylacetylhydrazones and s-triazole hydrazone derivatives (V) [J]. Chin Pharm J(中国药学杂志), 2015, 50(6):545-549.
[7] YOU Q D, LI Z Y, HUANG C H, et al. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification [J]. J Med Chem, 2009, 52(18):5649-5661.
[8] LI J, JIN Y, SHOU K J, et al. Design, synthesis and antitumor activity of quinolone derivatives [J]. Chin Pharm J(中国药学杂志), 2013, 48(23):2055-2060.
[9] GUO H Y, TIAN Z M, SUN L Y, et al. Synthesis of difloxacin hydrochloride [J]. Chin J Pharm(中国医药工业杂志),1992, 23(12):529-531.
[10] GIOVANELLA B C, STEHLIN J S, WALL M E, et al. DNA topoisomerase I-Targeted chemotherapy of human colon cancer in xenografts [J]. Science, 1989, 246(4933):1046-1048.

基金

国家自然科学基金资助项目(21306104, 21476128);浙江省教育厅科研项目(Y201329284)
PDF(1141 KB)

Accesses

Citation

Detail

段落导航
相关文章

/